Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

INTRODUCTION: The effect of certolizumab pegol (CZP) on patient-reported outcomes (PROs) was investigated in 1063 patients with rheumatoid arthritis (RA) from the REALISTIC trial (double-blind, placebo-controlled to week 12, open-label to week 28; randomized 4:1 [CZP:placebo]). Correlations between...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Res Ther
Hlavní autoři: Pope, Janet, Bingham, Clifton O., Fleischmann, Roy M., Dougados, Maxime, Massarotti, Elena M., Wollenhaupt, Jürgen, Duncan, Benjamin, Coteur, Geoffroy, Weinblatt, Michael E.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2015
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4662806/
https://ncbi.nlm.nih.gov/pubmed/26614481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0849-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky